CAMP

CAMP4 THERAPEUTICS CORPORATION

$4.33

-7.68%

SectorHealthcareIndustryBiotechnologyCountryUnited States

Overview AI Brief ChartChart & Performance Financials ExposureRevenue Exposure FilingsFilings & Red Flags ScoresScores & Valuation News Analysts InsidersInsiders & Short Interest Ownership

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Source: Yahoo Finance

Market Cap$271.7M

Dividend Yield0.00%

AnalystsStrong Buy+144.1% target

Beta1.38

AI summary

Price & performance

1M-21.1%

3M+3.1%

YTD-45.2%

1Y-3.5%

52-week range—

Beta1.38

Full chart and returns against a benchmark

Q-Score

44/ 100

Quality against peers; 50 is the peer median.

Growth65

Risk37

Performance47

Valuation35

Profitability42

Leverage55

Sentiment37

Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$3.5M+436.5%

Net income-$80.4M

Net margin—

Historical fundamentals

Revenue exposure

0%of revenue from outside the US

United States100%

Regions, segments, customers and suppliers

Valuation

CAMPIndustryP/E—89.69P/S51.0811.88EV/EBITDA—67.10P/B2.546.22PEG—4.02

Dividend yield0.00%

Every valuation metric

Historical Fundamentals

Revenue

Net Income

Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.

Latest Results

The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.

Metric	FY 2025	vs a year before	Q3 2026	vs a year before
Revenue	$3.5M	+436.5%	$1.9M	—
Net Income	-$80.4M	—	-$29M	—

Q-Scores

OverallCombines the categories below, except Sentiment

Industry 5744

Growth

Industry 7965

Risk

Industry 5537

Performance

Industry 6647

Valuation

Industry 2535

Profitability

Industry 4742

Leverage

Industry 6855

Sentiment

Industry 6037

Key Metrics

Fundamentals: trailing twelve months to Sep 2026, from the latest 10-K and 10-Qs.

Market Beta (5-factor)

IM 0.72SM 0.780.94

Market Cap

271.7M

Dividend Yield

IM 0.00%SM 0.00%0.00%

Volume

IM 693.1KSM 741.7K260K

Industry Market Share

0.02%

Sector Market Share

0.00%

IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.

Comparable Companies

The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.

Company	Market cap	P/E	EV/EBITDA	P/S	P/B	FCF yield	Implied growth	Revenue growth	Op. margin	ROE	Debt/equity
CAMPCAMP4 THERAPEUTICS CORPORATION	$271.7M	—	—	51.1	2.5	-9.7%	—	39.9%	—	-113.1%	0.0
ARCTArcturus Therapeutics Holdings Inc.	$270.6M	—	—	8.9	1.6	-23.1%	—	-68.7%	-311.2%	-51.7%	0.0
RCKTRocket Pharmaceuticals, Inc.	$268.9M	—	—	—	0.7	-63.4%	—	—	—	-4.7%	0.0
SABSSAB Biotherapeutics, Inc.	$276.6M	—	—	—	1.3	-19.8%	—	—	—	-38.2%	0.0
QTTBQ32 Bio Inc.	$279.2M	8.7	—	5.2	1.0	-7.2%	—	—	34.2%	11.2%	0.0
LRMRLarimar Therapeutics, Inc.	$279.4M	—	—	—	2.2	-55.9%	—	—	—	-135.5%	0.0
LCTXLineage Cell Therapeutics, Inc.	$263M	—	—	20.1	4.3	-9.3%	—	19.9%	-205.2%	-53.0%	0.0
CUVLClinuvel Pharmaceuticals Limited	$262M	11.3	8.8	4.1	1.4	4.5%	6.3%	5.2%	43.4%	12.3%	0.0
FULCFulcrum Therapeutics, Inc.	$284.1M	—	—	—	0.9	-23.3%	—	—	—	-27.4%	0.0
Industry median		11.7	20.2	7.7	2.2	-22.3%	9.9%	12.8%	-76.9%	-60.8%	0.0
CAMP percentile		—	—	85th	55th	69th	—	66th	—	29th	39th